These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24556870)

  • 1. Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers.
    van den Kerkhof TL; Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; Sanders RW
    AIDS; 2014 May; 28(8):1237-40. PubMed ID: 24556870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from humoral responses of HIV patients.
    McCoy LE; McKnight Á
    Curr Opin HIV AIDS; 2017 May; 12(3):195-202. PubMed ID: 28422783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Immunity Concomitantly Suppresses HIV-1 Progression.
    Qureshi H; Bhattacharya J
    Trends Microbiol; 2017 May; 25(5):334-335. PubMed ID: 28284876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of humoral immunity in host defense against HIV.
    Baum LL
    Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
    Euler Z; van den Kerkhof TL; van Gils MJ; Burger JA; Edo-Matas D; Phung P; Wrin T; Schuitemaker H
    J Virol; 2012 Feb; 86(4):2045-55. PubMed ID: 22156522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Neutralizing Antibodies: Magic Bullets against HIV?
    Julg B; Alter G
    Immunity; 2016 Jun; 44(6):1253-4. PubMed ID: 27332729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward an antibody-based HIV-1 vaccine.
    Hoxie JA
    Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study describes onset of broadly neutralizing antibody responses in HIV-infected individuals.
    von Bubnoff A
    IAVI Rep; 2011; 15(1):23. PubMed ID: 21449508
    [No Abstract]   [Full Text] [Related]  

  • 16. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.
    Euler Z; van Gils MJ; Boeser-Nunnink BD; Schuitemaker H; van Manen D
    PLoS One; 2013; 8(1):e54684. PubMed ID: 23372753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load.
    Hasselrot K; Bratt G; Hirbod T; Säberg P; Ehnlund M; Lopalco L; Sandström E; Broliden K
    AIDS; 2010 Jan; 24(1):35-43. PubMed ID: 19779318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.
    van Gils MJ; Bunnik EM; Burger JA; Jacob Y; Schweighardt B; Wrin T; Schuitemaker H
    J Virol; 2010 Apr; 84(7):3576-85. PubMed ID: 20071586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly neutralizing antibodies to prevent HIV-1.
    Cohen MS; Corey L
    Science; 2017 Oct; 358(6359):46-47. PubMed ID: 28983040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.